

REMARKS

Initially, the Applicants note that while the Office Action Summary reflects that claims 1-11 are pending in the application, claims 1-14 are pending.

In the Restriction, the Examiner defined two species:

- Species a): those claims directed towards injecting the first and second material sequentially or differently, and
- Species b): those claims directed towards injecting the first and second materials simultaneously.

The Examiner further stated that claims 1-11 are generic, and required the Applicants to include a listing of claims readable on each of the defined species. The Applicants believe that claims 12 and 14 (which has been amended above to depend from claim 1) are directed to species a), and claim 13 is directed to species b).

The Applicants elect to pursue the claims of Species a). Thus, the Applicants trust that claims 1-12 and 14 will be examined, and claim 13 will be withdrawn. Should the Examiner feel further communication would help prosecution, the Examiner is urged to call the undersigned at the telephone number provided below.

Respectfully Submitted,



Sean P. O'Hanlon
Reg. No. 47,252

Dated: May 3, 2006

Bingham McCutchen LLP
3000 K Street, NW
Suite 300
Washington, DC 20007
(202) 373-6029